Welcome to our dedicated page for Aditxt SEC filings (Ticker: ADTX), a comprehensive resource for investors and traders seeking official regulatory documents including 10-K annual reports, 10-Q quarterly earnings, 8-K material events, and insider trading forms.
Tracking a company that engineers immune-tolerance platforms like Aditxt means wading through dense scientific disclosures, layered risk factors, and frequent R&D updates. Whether you need 鈥淎ditxt 8-K material events explained鈥� before a clinical milestone or want 鈥淎ditxt insider trading Form 4 transactions鈥� to gauge management鈥檚 conviction, the raw SEC feed can feel impenetrable.
Stock Titan solves that problem. Our AI instantly converts every filing鈥攆rom an 鈥淎ditxt quarterly earnings report 10-Q filing鈥� to an 鈥淎ditxt annual report 10-K simplified鈥濃�攊nto clear briefs that spotlight transplant-tolerance progress, Adimune trial costs, and AditxtScore commercialization timelines. You鈥檒l also find 鈥淎ditxt SEC filings explained simply鈥� in a single dashboard. AG真人官方-time alerts flag 鈥淎ditxt Form 4 insider transactions real-time,鈥� so you see executive buys or sales the moment they post. Need deeper context? AI-generated redlines map pipeline spending, patent updates, and cash-runway changes across periods.
Professionals use these insights to:
- Compare immunotherapy R&D spend quarter over quarter
- Monitor 鈥淎ditxt proxy statement executive compensation鈥� against shareholder returns
- Spot dilution risk highlighted in capital-raise 8-Ks
Because every document is cross-linked, 鈥渦nderstanding Aditxt SEC documents with AI鈥� takes minutes, not hours. Historical dashboards overlay revenue guidance with 鈥淎ditxt earnings report filing analysis,鈥� while footnote extraction pulls trial enrollment numbers straight from the MD&A. If your strategy hinges on timely signals鈥攆rom 鈥淎ditxt executive stock transactions Form 4鈥� to emergent licensing deals鈥攖his page delivers the complete picture as soon as EDGAR releases it.
Bank of Montreal (BMO) is offering US$425,000 of Senior Medium-Term Notes, Series K 鈥� 鈥淒igital Return Buffer Notes鈥� 鈥� maturing 3 August 2026. The notes are linked to the worst performer of three U.S. equity benchmarks: the S&P 500, NASDAQ-100 and Russell 2000 (each a 鈥淩eference Asset鈥�).
Key economic terms:
- Digital Return: 10.40% payable at maturity if the closing level of the Least Performing Reference Asset on 29 July 2026 (the Valuation Date) is 鈮� 85% of its 27 June 2025 Initial Level (鈥淒igital Barrier鈥�).
- Buffer: first 15% downside is absorbed. If the Least Performing Reference Asset drops >15%, principal is reduced point-for-point beyond the buffer, exposing investors to a maximum loss of 85%.
- No periodic coupons; single payment at maturity.
- Issue price: 100%; agent鈥檚 commission 0.375%; estimated initial value: $981.99 per $1,000, reflecting embedded fees and hedging costs.
- Credit exposure: unsecured, unsubordinated obligations of BMO; CUSIP 06376EMN9; not FDIC or CDIC insured; not exchange-listed.
Illustrative payouts: any Final Level 鈮� 85% triggers a fixed $1,104 per $1,000 note (10.40% gain). A Final Level of 80% returns $950 (-5%); 60% returns $750 (-25%); 0% returns $150 (-85%). Upside is capped at 10.40% irrespective of index performance.
Risk considerations include potential loss of up to 85% of principal, limited upside versus direct index exposure, secondary-market illiquidity (no listing; dealer market making discretionary), BMO credit risk, tax uncertainty (treated as prepaid derivative contracts), and a price-to-public that exceeds the bank鈥檚 modeled value.
The product may appeal to investors with a moderately bullish to sideways view on large-, mega- and small-cap U.S. equities over the next ~13 months who are willing to trade upside beyond 10.40% for a 15% buffer and accept issuer credit and liquidity risk.
Geron Corporation (ticker GERN) has filed a Form S-8 to register an additional 26 million shares of common stock for employee benefit purposes:
- 20 million shares for the 2018 Equity Incentive Plan
- 6 million shares for the 2014 Employee Stock Purchase Plan (ESPP)
For investors, the filing signals continued use of equity-based compensation, which can motivate employees but may incrementally dilute existing shareholders as the newly registered shares are issued over time.
Aditxt has reported several significant financial transactions in this 8-K filing. Two senior executives provided short-term loans to the company: CEO Amro Albanna ($90,000) and CIO Shahrokh Shabahang ($100,000). These unsecured promissory notes carry a 7.5% interest rate and are due by July 20, 2025.
Additionally, the company issued a warrant to an unnamed consultant as part of a new marketing services agreement. Key warrant terms include:
- Right to purchase up to 600,000 shares of common stock
- Exercise price of $2.00 per share
- Two-year term
- Ownership limitation of 4.99% (or 9.99% at holder's election)
Both the promissory notes and warrant were issued under Section 4(a)(2) Securities Act exemption. The company, listed on Nasdaq as ADTX, is classified as an emerging growth company. These transactions suggest potential cash flow challenges and efforts to enhance investor relations.
Aditxt has filed an S-1 registration statement for the resale of up to 50 million shares of common stock under a $150 million purchase agreement with Seven Knots. The company has already sold 932,549 shares for approximately $23.9 million under this agreement.
Key business highlights:
- Founded in 2017, Aditxt focuses on transforming healthcare innovations into commercial products across immune health, precision health, population health, women's health, and neurologic health
- Business model involves securing innovations through licensing/acquisition, providing resources for development, and monetizing through commercialization
- Current commercial programs include Adimune (immune modulation technology) and Pearsanta (precision diagnostics)
- Company operates as a non-accelerated filer, smaller reporting company, and emerging growth company
The stock currently trades on Nasdaq under symbol ADTX at $1.42 per share (as of June 18, 2025). The company has implemented a digital asset treasury strategy that includes potential bitcoin investments. Notable partnerships include Stanford University and Mayo Clinic.
FAQ
What is the current stock price of Aditxt (ADTX)?
What is the market cap of Aditxt (ADTX)?
What is the primary focus of Aditxt Inc?
What are the key product programs of Aditxt Inc?
How does Aditxt Inc generate revenue?
What is the significance of immune tolerance in Aditxt Inc's work?
How does Aditxt Inc differentiate itself from other biotech companies?
What role does research and development play at Aditxt Inc?
How do the products of Aditxt Inc impact patient care?
What industry sectors does Aditxt Inc operate within?
